LKFT vs NBTX
Galapagos NV and Nanobiotix S.a., side by side — 8 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | LKFT | NBTX |
|---|---|---|
| Revenue | €1.1B | €32.6M |
| Net income | €320.9M | €-24.0M |
| Gross margin | 97.3% | — |
| Net margin | 28.9% | −73.5% |
| Return on equity | — | — |
| Diluted EPS | €4.87 | −€0.50 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | €-271.2M | €-34.0M |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 20.15× | 1.09× |
| Revenue CAGR 5y | 18.4% | 67.0% |
| Profit CAGR 5y | — | — |
LKFT bills 34.1× the revenue of NBTX, and NBTX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
8 years side by side
| Fiscal year | LKFT | NBTX |
|---|---|---|
| FY2025 | €1.1B | €32.6M |
| FY2024 | €275.6M | €-7.2M |
| FY2023 | €239.7M | €36.2M |
| FY2022 | €241.2M | €4.8M |
| FY2021 | €234.4M | €2.6M |
| FY2020 | €478.1M | €2.5M |
| FY2019 | €834.9M | €2.5M |
| FY2018 | €278.7M | €3.5M |
Net income by year
Bottom line
| Fiscal year | LKFT | NBTX |
|---|---|---|
| FY2025 | €320.9M | €-24.0M |
| FY2024 | €74.1M | €-68.1M |
| FY2023 | €211.7M | €-39.7M |
| FY2022 | €-218.0M | €-57.0M |
| FY2021 | €-103.2M | €-47.1M |
| FY2020 | €-305.4M | €-33.6M |
| FY2019 | €149.8M | €-50.9M |
| FY2018 | €-29.3M | €-30.3M |
Advertisement
AdSense · Rectangle 336×280